Sinovac Biotech Ltd. announced that the South African Health Products Regulatory Authority (SAHPRA) granted conditional registration to SINOVAC CoronaVac in aged 18 and above adults, based on acceptable safety, quality, and efficacy data submitted. The vaccine is administered intramuscularly in two doses with a 14 to 28-day interval. The CoronaVac was previously authorized for emergency use with conditions by the SAHPRA on July 3, 2021.

Subsequent to the approval, SINOVAC has been committing to the conditions, reporting the results of ongoing studies and conformance with pharmacovigilance activities as outlined in the approved risk management plan and submitting periodic safety updates. All the evidence suggested that the SINOVAC COVID-19 vaccine was safe and effective. SINOVAC COVID-19 vaccine has been available in more than 60 countries, with a total supply of almost 2.9 billion doses.